FHND9041
- Generic Name
- FHND9041
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06759857
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Sensitizing Mutation
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Yongchang Zhang
- Target Recruit Count
- 124
- Registration Number
- NCT06521034
- Locations
- 🇨🇳
Yongchang Zhang, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath